Scienmag

JANUARY 11, 2022

Enhancers are regions of DNA that do not code for proteins, but control how genes are expressed. Super-enhancers are clusters of enhancers that together regulate genes with important roles in cell identity. Jude Children’s Research Hospital studied the Vsx2 super-enhancer and its role in the development of the retina.

Development 80

Development DNA Gene Protein 80

Drug Discovery World

MAY 18, 2023

Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. p62 protein forms a membrane-less cytosolic organelle called p62 body and helps in the selective removal of toxic cellular waste through autophagy.

Protein 52

Protein Scientist Medicine Regulation 52

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. RA: What is the current state of the cancer research industry? Mark Garner, PhD., MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

DECEMBER 3, 2020

New Tau Protein is Abnormal in Very Early Alzheimer’s Disease. Investigators with the University of Gothenburg identified new forms of tau protein that become abnormal in the very early stages of Alzheimer’s disease, even before the development of cognitive problems. Here’s a look at some of the more interesting ones.

Protein 52

Protein Research Regulation Gene 52

The Pharma Data

JUNE 14, 2023

Scientists discover small RNA that regulates bacterial infection People with weakened immune systems are at constant risk of infection. However, researchers at the Georgia Institute of Technology have identified the major mechanism behind the transition between chronic and acute P. aeruginosa infections. and Nelson D.

RNA 40

RNA Regulation Scientist Bacteria 40

Scienmag

MAY 9, 2021

New research presented at this year’s European Congress on Obesity (held online, 10-13 May) finds evidence that structures called inflammasomes (a part of the innate immune system that helps to regulate inflammation) could play an important role in the development of obesity-associated colon cancer.

Protein 70

Protein Research Regulation Development 70

The Pharma Data

MARCH 7, 2022

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports.

Protein 52

Protein Gene Genome Genomics 52

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1.

Protein 52

Protein Genome Genomics Research 52

XTalks

JUNE 11, 2024

The complexity of lupus, combined with its significant impact on individuals and communities, makes it a critical area of focus for rheumatology research. Dr. Askanase shares her insights on the crucial role of patient voices in shaping research, offering hope for new, more effective lupus treatments.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 13, 2023

Capivasertib is an investigational oral therapy and a potent adenosine triphosphate (ATP)-competitive inhibitor of all three AKT [protein kinase B] isoforms (AKT1/2/3). The regulator will announce its decision during the fourth quarter of 2023. AstraZeneca stated that its NDA is being reviewed under Project Orbis.

HR 245

HR Hormones Trials Protein 245

pharmaphorum

FEBRUARY 25, 2022

A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development. Prior to this latest development, research into the human ZGA was limited to human embryos at a later stage of growth, under stringent UK regulations.

Research 69

Research Genome Genomics Protein 69

Drug Discovery World

SEPTEMBER 1, 2022

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

Antibody 52

Antibody In-Vitro Development Recombinant Antibody 52

Drug Discovery World

MAY 21, 2024

Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. Existing antibody discovery methods have mostly failed for certain target groups, such as G protein-coupled receptors (GPCRs) and ion channels.

Antibody 59

Antibody Development FDA Approval Contract Manufacturing 59

Pharmaceutical Technology

JANUARY 25, 2023

Development of PROTACs (PROteolysis TArgeting Chimeras) has advanced fairly rapidly as excitement grows over their potential to selectively degrade proteins that are involved in various diseases, including cancer. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.

Protein 130

Protein Bioavailability Development Scientist 130

Drug Discovery World

MARCH 3, 2023

SiSaf will develop miRNA Bio-Courier formulations that will be tested in pancreatic cancer models in Professor Aigner’s laboratory. miRNAs are involved in the regulation of various physiological and pathological processes. miRNAs are involved in the regulation of various physiological and pathological processes.

Development 52

Development RNA Drug Delivery Regulation 52

Drug Discovery World

APRIL 1, 2024

An analysis of how brains with different forms of autism develop has revealed common underlying mechanisms that may respond to existing medications. Diana Spencer, Senior Digital Content Editor, DDW The post Study of different autism types reveals common underlying mechanism appeared first on Drug Discovery World (DDW).

Protein 59

Protein Regulation Genetics Drugs 59

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. The role of NfL NfL is a protein found inside nerve cells that conduct impulses and messages to and from the brain (scientifically termed myelinated axons).

Development 59

Development Drugs Trials Clinical Trials 59

XTalks

JULY 14, 2022

For example, when T cells (a type of white blood cells that fight off infections and cancer) are activated in our immune systems, thousands of proteins in these cells change. The proteins are interconnected and changes in one protein level can impact that of another. Using CRISPR Technology to Disrupt Networks of Immune Genes.

Gene 98

Gene Regulation Protein Gene Editing 98

Drug Discovery World

MAY 24, 2023

Altering the chemical properties of an anti-nausea drug enables it to enter an interior compartment of the cell and provide long-lasting pain relief, according to a new study led by researchers at NYU College of Dentistry’s Pain Research Center. The researchers genetically modified mice to express the human NK1 receptor.

Research 52

Research Drugs Protein FDA Approval 52

The Pharma Data

SEPTEMBER 30, 2021

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

Protein 52

Protein Scientist Antibody Research 52

Drug Discovery World

APRIL 11, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells. USP30 is a (de)ubiquitylation (DUB) implicated in neurodegenerative diseases that regulates the clearance of damaged mitochondria in a process called mitophagy.

Research 52

Research Drugs Life Science RNA 52

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Melatonin, which regulates the body’s circadian rhythm and sleep-wake cycle, is also available in pill form for use as a sleep aid.

Research 98

Research Hormones Protein Regulation 98

pharmaphorum

JANUARY 11, 2023

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and immunology. before disease-related proteins are expressed). before disease-related proteins are expressed).

Protein 105

Protein Regulation FDA Approval Licensing 105

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. But, until now, scientists lacked an understanding of what the chemical tag does, despite many years of research.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Drug Discovery World

NOVEMBER 14, 2022

Find out more: New human beta cell model enables discoveries in diabetes research . Based on research into adrenergic signaling by professor Tore Bengtsson at Stockholm University, ATR-258 is a small molecule therapy that works by selectively stimulating b2-adrenergic receptors to translocate GLUT4 to the cell membrane. .

Development 52

Development Gene Therapy Drugs Gene 52

The Pharma Data

MAY 30, 2023

New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer’s disease Why do some people develop Alzheimer’s disease while others don’t? University of Pittsburgh School of Medicine researchers appear to have found the answer. associate professor of psychiatry and neurology at Pitt.

Development 40

Development Protein Research Scientist 40

The Pharma Data

MARCH 30, 2021

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio.

Protein 52

Protein Licensing Licensing Containment 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Introduction to the CRUK Beatson Institute The first speaker was Professor Owen Sansom, Director of the Cancer Research UK Beatson Institute, who gave two presentations.

Research 52

Research Drugs In-Vitro Insulin 52

Drug Discovery World

NOVEMBER 15, 2023

A new compound reversed four types of chronic pain in animal studies, according to research led by New York University (NYU) College of Dentistry’s Pain Research Center. A first-in-class small molecule Protein CRMP2 is a key regulator of the Cav2.2 Gabapentin mitigates pain by binding to the outside of the Cav2.2

Scientist 52

Scientist Protein Regulation Clinical Trials 52

Pharmaceutical Technology

MARCH 9, 2023

The production of antibodies in response to proteins expressed during cancer development serves as a biomarker. The production of serum antibodies results from regulated differentiation of B lymphocytes into antibody secreting cells (ASCs), plasma blasts, and plasma cells. Immutep Ltd.

Antibody 147

Antibody Production Protein Regulation 147

Drug Discovery World

JANUARY 17, 2024

Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. Scientists from Fujita Health University have shown that mitochondria play essential roles during muscle development, regeneration and maintenance.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “With new variants – like Omicron and B.1.640.2

Protein 126

Protein Vaccination Vaccine Immune Response 126

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed using Immuno-STAT technology.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100